Ross Muken News
-
Wachtell, Lipton, Rosen & Katz and Wilmer Cutler Pickering Hale & Dorr LLP acted as legal advisers to Thermo Fisher Scientific Inc., the second-biggest maker of life-sciences equipment by market value, which agreed to buy Life Technologies Corp. for $13.6 billion in cash in a deal that expands its reach in medical testing.
-
Thermo Fisher Scientific Inc., the second-biggest maker of life-sciences equipment by market value, agreed to buy Life Technologies Corp. for $13.6 billion in cash in a deal that expands its reach in medical testing.
-
Agilent Technologies Inc., with a valuation cheaper than 96 percent of peers, would enrich shareholders by breaking up and focusing on its faster-growing biological- and chemical-testing businesses.
-
Life Technologies Corp. got takeover offers from a private-equity group including Blackstone Group LP, and from Thermo Fisher Scientific Inc., for as much as $11.8 billion, said people familiar with the matter.
-
A takeover of Life Technologies Corp. at one of the lowest multiples on record would still be better for shareholders than no deal at all.
-
Life Technologies Corp.’s Chief Executive Officer Greg Lucier said his company will take the top spot in genetic sequencing next year ahead of current industry leader Illumina Inc.
-
Express Scripts Holding Co. rose after the largest U.S. processor of drug prescriptions gave a profit forecast that exceeded analysts’ lowered estimates.
-
Life Technologies Corp., a maker of DNA-sequencing equipment and laboratory materials, is in discussions with private-equity firms and health-care companies about a potential sale of the company, according to people familiar with the process.
-
Cardinal Health Inc., the second- largest U.S. drug distributor by revenue, said it agreed to buy closely held AssuraMed for $2.07 billion to add home delivery services of health-care products.
-
Roche Holding AG Chairman Franz Humer may have put a lid for now on a year’s worth of speculation by telling a Swiss newspaper that a Roche deal to buy U.S. genetics company Illumina Inc. is off the table. Illumina shares fell the most in 15 months.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page